significant publications on infectious diseases pharmacotherapy in 2015 2017 jessica t. babic参考.pdf

该【significant publications on infectious diseases pharmacotherapy in 2015 2017 jessica t. babic参考 】是由【小舍儿】上传分享，文档一共【15】页，该文档可以免费在线阅读，需要了解更多关于【significant publications on infectious diseases pharmacotherapy in 2015 2017 jessica t. babic参考 】的内容，可以使用淘豆网的站内搜索功能，选择自己适合的文档，以下文字是截取该文章内的部分文字，如需要获得完整电子版，请下载此文档到您的设备，方便您编辑和打印。:..,.,BCPS,’’(ID)pharma-MedicalCenter,UniversityofHoustoncotherapypublishedinthepeer-reviewedliteraturein2015,asnominatedCollegeofPharmacy,Houston,,areAmeliaSofjan,.,,UniversityofHoustonCollegeofPharmacy,Houston,,.,Tomballaskedtonominatearticlespublishedinprominentpeer-reviewedjournalsRegionalMedicalCenter,Tomball,-KellyEchevarria,.,BCPS--relatedtopicsAQID,SouthTexasVeteransHealthCareand10articlesspecificallyrelatedtohumanimmunodeficiencyvirus(HIV)System,SanAntonio,(AIDS),.,.,Inanationalonlinesurvey,membersoftheSocietyofInfectiousDiseasesBCPS-AQID,HoustonMethodistHospitalPharmacyServices,Houston,Pharmacists(SIDP)-Wai-,.,BCPS,macotherapyand1articlecontributingtoHIV/,the361SIDPmemberssurveyed,153(42%)and76(21%)participatedinGalveston,-relatedarticlesandHIV/AIDS-relatedarticles,,.,BCPS,-rankedpublications(10generalID-relatedar-DivisionofPharmacy,UniversityofTexasMDAndersonCancerCenter,ticlesand1HIV/AIDS-relatedarticle),TX,andCenterforAntimicrobialResistanceandMicrobialGenomics,-relatedpublica-UTHealthMcGovernMedicalSchool,Houston,,,.,BCPS-ThisreviewofimportantIDpharmacotherapypublicationsin2015maybeAQID,,HoustonMethodistHospital,Keywords:municablediseases,drugtherapy,Houston,,publications,therapeuticuseAmJHealth-;74:238-52vastamountofinformationre-TexasMedicalCenterandotherinsti-Agardingthediagnosisandtreat-(ID)isThepurposesofHIDNaretoestab-,sharebest-practice2016usingthekeywordsinfectiousmodels,andhostpresentationsfromdiseasesandHIVidentified24,,16,436articlesonthoserespectivetop-HIDNmentorsresidents,fellows,--Tosupportongoingeffortstoiden-lengesofmultidrug-resistantpatho-–relatedpublica-TheHoustonInfectiousDiseasestions,1-(HIDN)consistsofIDclini-tonominatearticlespublishedin(kkperez@).cians,includingphysicians,pharma-2015thattheybelievedhadasignifi-cists,microbiologists,andresearch-cantimpactonIDpharmacotherapy,,themajorityofwhompracticeatincludingarticlesonhumanimmu-238AMJHEALTH-SYSTPHARM|VOLUME74|NUMBER4|FEBRUARY15,2017:..INFECTIOUSDISEASESSPECIALFEATUREnodeficiencyvirus(HIV)ers,surgicalwounds,indwellingandacquiredimmunodeficiencysyn-KEYPOINTSprostheticdevices,hemodialysis)”indrome(AIDS).Allnominatedarticles?-werepublishedbetweenJanuary1thatcefepimeisinefficientacteristicprofileofpatientswithIEandDecember31,2015,inprominentforcefepime-susceptiblealsohasshiftedoverthepastdecadepeer-reviewedjournals(.,Anti-dose-dependentEnterobactertowardanincreasedmeanpatientmicrobialAgentsandChemotherapy,,anincreasedproportionofpa-ClinicalInfectiousDiseases,Journal?ArandomizedcontrolledtrialtientswithprostheticvalvesorotheroftheAmericanMedicalAssociation,paredwithcardiacdevices,andadecreasedpro-NewEnglandJournalofMedicine).voriconazolemonotherapy,portionofpatientswithrheumaticInlateDecember2015,aninvita--mitteeconductedreviewsoftheveywase-mailedtomembersofthevivalinsubgroupsofpatientsliteraturepublishedbetweenJanuarySocietyofInfectiousDiseasesPharma-(SIDP).Membersweredirectedprevious2005versionoftheAHAIEtoalistofthenominatedarticles(55?–relatedthatb-lactamtherapyimprovesThe2015guidelineupdateempha-and10HIV/AIDSpharmacotherapy–mendationsarerelatedarticles)andwereaskedtomethicillin-susceptibleStaphy-intendedtosupportbutdonotsuper-usaureusbacteremiasedeclinicaldecision-makingwithre--?Resultsofarandomizedcon--therapyinitiationinHIV-+countsofclinicallyevaluatedusingthemodifiedarticlesnotincludedinthesurvey;>500cells/mm3duetosignifi-“Dukecriteria”--andnon–AIDS--sponsesfrommembersnotcurrentphyinallpatientswithsuspectedIE,withtheliterature,votersweregivenfollowedbytransesophagealechocar-theopportunitytooptoutofvotingdiography(TEE)(-valves,previousIE,orheartfailure),-the361SIDPmemberssurveyed,153professionalsfromtheto-highclinicalsuspicionofIE,andAmericanHeartAssociation8(42%)and76(21%)membersvotedforin“difficultimagingcandidates”forgeneralID-relatedarticlesandHIV/Infectiveendocarditis(IE)isde-whomTEEisnotclinicallypossibleorAIDS-relatedarticles,-rankedarticlesof2015en-prostheticheartvalve,theendocar-The2015updatehasanewsectioncompassedawiderangeofIDtopics,dialsurface,oranindwellingcathe-focusedonantimicrobialtherapeuticandthe11highest-rankedpapers(-generalID-relatedarticlesand1HIV/,000populationintanceofbactericidalantibiotics,theAIDS-relatedarticle),000populationroleoftheinoculumeffect,andtheordingin2009,withnochangeinthe15-rabilityofdrugsintotheveg-totheleadauthor’(PK)listsofthetop20generalID-relatedthe12--andpharmacodynamic(PD)dosingand10HIV/AIDS-relatedarticlesap-ogyandpatientcharacteristicshaveconsiderationsareincludedinanef-pearinTables1and2,-37changedsincepublicationofthelat-forttofullyoptimizeantibioticdosingestversionofAmericanHeartAssoci-(AHA):usaureushasemergedtreatmentselectionpressurefavoringdiagnosis,antimicrobialastheleadingetiologicagentinIE,,andmanagementofmostlydueto“increasedhealthcareForpatientswithIEinvolvingana-complications:ontact([.],intravascularcath-tiveorprostheticvalveorotherpros-AMJHEALTH-SYSTPHARM|VOLUME74|NUMBER4|FEBRUARY15,2017239:...(%)(n=153)parisonoftheeffectivenessandsafetyoflinezolidanddaptomycin83(54)ycin-albloodstreaminfection::diagnosis,antimicrobialtherapy,and80(52)plications:-(52)parativeeffectivenessofbeta-ycinfor77(50)treatmentofmethicillin-(47)withpiperacillin-tazobactamforpatientswithextended-spectrumb-(42)intermittentbeta-(39):58(38)esinpatientsinfectedbycefepime-susceptibledose--seated53(35)methicillin--ycinforsevereinfections52(34)usaureus:(32)(31)patients:(31)(29)antibiotictherapyforMSSAbacteremia:(IDSA)clinicalpractice45(29)(26)esamongpatientswithmethicillin-:40(26)(24)catheter--acquiredpneumoniain33(22)(20)usaureusbacteremia:ameta--producingKlebsiellapneumoniae:30(20)=SocietyofInfectiousDiseasesPharmacists,MSSA=methicillin-usaureus,KPC=-SYSTPHARM|VOLUME74|NUMBER4|FEBRUARY15,2017:...(%)(n=76)b128LundgrenJDetal.,(41),coformulated9(12)withelvitegravir,cobicistat,andemtricitabine,forinitialtreatmentofHIV-1infection:tworandomiseddouble-blind,phase2,non--demandpreexposureprophylaxisinmenathighriskforHIV-18(11)-exposureprophylaxistopreventtheacquisitionofHIV-17(9)infection(PROUD):effectivenessresultsfromthepilotphaseofapragmaticopen--dailydolutegravirversusdarunavirplusritonavirfortreatment-7(9)naiveadultswithHIV-1infection(FLAMINGO):96weekresultsfromarandomised,open--basedpreexposureprophylaxisforHIVinfectionamong5(7)(7)proteasei